RedHill Biopharma Ltd.
RDHL · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| FCF Yield | -71.74% | -52.32% | -9.97% | -7.09% |
| EV / EBITDA | -0.40 | -1.02 | -6.25 | -11.56 |
| Quality | ||||
| ROIC | 59.19% | 59.19% | 88.73% | 80.55% |
| Gross Margin | 60.60% | 60.60% | 67.32% | 67.32% |
| Cash Conversion Ratio | 1.21 | 1.21 | 0.61 | 0.61 |
| Growth | ||||
| Revenue 3-Year CAGR | -35.59% | -44.80% | -49.32% | -56.44% |
| Free Cash Flow Growth | 0.00% | -57.24% | 0.00% | 48.40% |
| Safety | ||||
| Net Debt / EBITDA | 1.26 | 1.26 | 2.27 | 0.84 |
| Interest Coverage | -4.28 | -4.28 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.25 | 0.25 | 0.24 | 0.24 |
| Cash Conversion Cycle | 542.09 | 497.52 | -306.50 | 333.50 |